Reumatologia: Exames Laboratoriais Online (Laboratory Tests in Rheumatology)

■ Laboratory tests in Rheumatology: a rational approach

E Sureh

Cleveland Clinic Journal of Medicine 2019: vol 86 (3): 198-210

https://www.mdedge.com/ccjm/article/195311/rheumatology/laboratory-tests-rheumatology-rational-approach

 

■ Laboratory evaluation in rheumatic diseases

M Birtane, S Yavuz, N Tastekin

World J Methodol  2017, vol 7 (1): 1-8

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366934/

 

■ Rheumatoid fator as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: results of a cohort study

Pedro Santos-Moreno, Guillermo Sánchez, Carlos Castro

Medicine (Baltimore) 2019 Feb; 98(5): e14181

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380754/

 

■ Feasibilty of cardiovascular disease risk assessments in rheumatology outpatient clinics: experinces from the nationwide NOCAR project

Eirik Ikdahl, Silvia Rollefstad, Grunde Wibetoe et al

RMD Open. 2018; 4(2): e000737

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173264/

 

■ Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care

Denis Poddubnyy, Johanna Callhoff, Inge Spiller et al

RMD Open. 2018; 4(2): e000825

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336095/

 

■ Protocols on classification, monitoring and therapy in children´s rheumatology (PRO-KIND): results of the working group polyarticular juvenile idiopathic arthritis

Gerd Horneff, Ariane Klein, Gerd Ganser et

Pediatr Rheumatol Online J. 2017; 15: 78.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678777/

 

■ Assessment and management of musculoskeletal disorders among patient living with HIV

Dr Karen Walker-Bone, Dr Erin Doherty, et al

Rheumatology (Oxford). 2017 Oct 1; 56(10): 1648–1661

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483171/

 

■ How immunological profile drives clinical phenotype of primary Sjögren´s syndrome at diagnostic: analysis of 10500 patients (Sjögren Big Data Project)

Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, et al

Sjögren Big Data Consortium.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):102-112

https://www.clinexprheumatol.org/article.asp?a=12899

 

■ Emerging technologies in autoantibody testing for rheumatic diseases

Nancy J. Olsen, May Y. Choi, Marvin J. Fritzler

Arthritis Res Ther. 2017; 19: 172

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525353/

 

■ Personalized medicine in rheumatology: the paradigm of serum autoantibodies

Sirotti S, Generali E, Ceribelli A, Isailovic N, De Santis M, Selmi C.

Auto Immun Highlights. 2017 Dec;8(1):10

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507804/

 

■ Are cytokines (IL-6, CRP and adiponectin) associated with bone mineral density in a young adult birth cohort?

Ana Maria Baptista Menezes, Paula Duarte Oliveira, Helen Gonçalves et al

BMC Musculoskelet Disord. 2018; 19: 427

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267914/

 

■ Ácidos graxos ômega-3, estado inflamatório e marcadores bioquímicos de pacientes com lúpus eritematoso sistêmico: estudo piloto

Borges, Mariane Curado et al

Rev. Bras. Reumatol., Dec 2017, vol.57, no.6, p.526-534

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600526&lng=pt&nrm=iso&tlng=pt

 

■ Independência de isoformas de transferrina deficiente em carboidrato e peptídeos citrulinados cíclicos na artrite reumatoide

Gudowska, Monika et al

Rev. Bras. Reumatol., May 2017, vol.57, no.3, p.185-189

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000300185&lng=pt&nrm=iso&tlng=pt (Portuguese)

 

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000300185&lng=pt&nrm=iso&tlng=en (English)

 

■ Calprotectin in rheumatic diseases

Francesca Ometto, Lara Friso, Davide Astorri et al

Exp Biol Med (Maywood) 2017 Apr; 242(8): 859–873

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407536/

 

■ EULAR/ACR Classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

Ingrid E Lundberg, Anna Tjärnlund, Matteo Bottai et al

the International Myositis Classification Criteria Project consortium, the Euromyositis register, the Juvenile dermatomyositis cohort biomarker study and repository (JDRG) (United Kingdom and Ireland)

Ann Rheum Dis. 2017 Dec; 76(12): 1955–1964

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736307/

 

■ Detecção de anticorpos antinucleares por imunofluorescência indireta em células HEp-2: definindo a diluição de triagem adequada para o diagnóstico das doenças reumáticas autoimunes.

Brito, Fabiano de Almeida et al.

Rev. Bras. Reumatol., Fev 2014, vol.54, no.1, p.13-20

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042014000100013&lng=pt&nrm=iso

 

■ Febre reumática: atualização dos critérios de Jones à luz da revisão da American Heart Association – 2015

Pereira, Breno Álvares de Faria, Belo, Alinne Rodrigues and Silva, Nilzio Antônio da

Rev. Bras. Reumatol., Aug 2017, vol.57, no.4, p.364-368

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000400364&lng=pt&nrm=iso&tlng=pt (portuguese)

 

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000400364&lng=pt&nrm=iso&tlng=en (english)

 

■ Acute rheumatic fever and rheumatic heart disease

Jonathan R. Carapetis, Andrea Beaton, Madeleine W. Cunningham et al

Nat Rev Dis Primers. 2016 Jan 14; 2: 15084

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810582/

 

■ Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines

Busger Op Vollenbroek FTM, Doggen CJM, et a

PLoS One. 2018 Mar 23;13(3):e0194401

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865732/

 

■ Autoantibodies in juvenile-onset myositis: their diagnostic value in and associated clinical phenotype in a large UK cohort

Tansley SL, Simou S, Shaddick G et al

J Autoimmun. 2017 Nov;84:55-64

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656106/

 

■ Biomarkers to guide clinical therapeutics in rheumatology?

William H. Robinson, Rong Mao

Curr Opin Rheumatol. 2016 Mar; 28(2): 168–175

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770786/

 

■ Serum markers in rheumatology arthritis: a longitudinal study of patients undergoing infliximab treatment

O Selaas, H H Nordal, A Halse et al

Int J Rheumatol 2015, 2015: 276815

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695666/

 

■ Gout: an old disease in new perspctive – a review

Gaafar Ragab, Mohsen Elshahaly, Thomas Bardin

J Adv Res. 2017 Sep; 8(5): 495–511

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512152/

 

■ Gout classification criteria: update and implications

Ana Beatriz Vargas-Santos, William J. Taylor, Tuhina Neogi

Curr Rheumatol Rep. 2016 Jul; 18(7): 46

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981244/

 

■ 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

Tuhina Neogi, Tim L Th A Jansen, Nicola Dalbeth et al

Ann Rheum Dis. 2015 Oct; 74(10): 1789–1798

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602275/

 

■ Systemic lúpus erythematosus biomarkers: the challeging guest

Cristina Arriens, Jonathan D. Wren, Melissa E. Munroe, Chandra Mohan

Rheumatology (Oxford) 2017 Apr; 56(Suppl 1): i32–i45

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850341/

 

■ Biomarkers of (osteo) arthritis

Ali Mobasheri, Yves Henrotin

Biomarkers. 2015 Nov 17; 20(8): 513–518

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840279/

 

■ Biomarkers in connective tissue diseases

Neelakshi R. Jog, Judith A. James

J Allergy Clin Immunol. 2017 Dec; 140(6): 1473–1483

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819750/

 

■ IV Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2

Francescantonio, Paulo Luiz Carvalho et al

Rev. Bras. Reumatol., Fev 2014, vol.54, no.1, p.44-50

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042014000100044&lng=pt&nrm=iso

 

■ Clinical and serological features of patients referred through a Rheumatology triags system because antinuclear antibodies

Christie Fitch-Rogalsky, Whitney Steber, Michael Mahler et al

PLoS One. 2014; 9(4): e93812.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976309/

 

■ Rheumatoid arthritis disease activity measures

American College of Rheumatolology Recommendations for use in clinical practice

J Anderson, L Caplan, J Yazdany et al

Arthritis Care Res (Hoboken). 2012 May; 64(5): 640–647

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028066/

 

■ Análise crítica do teste de anticorpos antinúcleo (FAn) na prática clínica

Dellavance, Alessandra, Leser, Paulo Guilherme and Andrade, Luís Eduardo Coelho

Rev. Bras. Reumatol., Ago 2007, vol.47, no.4, p.265-275

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042007000400005&lng=pt&nrm=iso

 

■ Valor diagnóstico do anticorpo antipeptídeo citrulinado cíclico na artrite reumatoide

Silva, Aldifran Ferreira da et al.

Rev. Bras. Reumatol., Jun 2006, vol.46, no.3, p.174-180.

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042006000300003&lng=pt&nrm=iso

 

■ Dosagem sérica de adenosina deaminase em lúpus eritematoso sistêmico: ausência de associação com atividade de doença.

Lima, Isabella, Néri, Fátima and Barreto Santiago, Mittermayer

Rev. Bras. Reumatol., Out 2005, vol.45, no.5, p.273-279

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042005000500002&lng=pt&nrm=iso

 

■ by Dr Paulo Fernando Leite

Cardiologia – Centro Médico Unimed BH

Rua Gonçalves Dias 202

Belo Horizonte/MG/Brasil

tel 40204020

CRMMG: 7026

Email: pfleite1873@gmail.com

Síndromes Mielodisplásicas Online (Myelodysplastic Syndromes)

¨As síndromes mielodisplásicas (SMDs) são caracterizadas por uma desordem clonal de células primordiais (stem cell) e hematopoese ineficaz que levam à displasia de uma ou mais linhagens celulares da medula óssea, citopenias periféricas e instabilidade genética, as quais aumentam o risco de transformação à leucemia mieloide aguda. Esse grupo heterogêneo de doenças hematopoéticas pode surgir como doença primária, que possui etiologia variada e não completamente definida, ou secundária ao tratamento quimioterápico ou radioterápico para outras neoplasias. O surgimento e aprimoramento de tecnologias de diagnóstico geraram uma melhor compreensão dos processos envolvidos na gênese e evolução das SMDs, o que possibilitou o desenvolvimento de marcadores de diagnóstico e acompanhamentos cada vez mais precoces e específicos. No ano de 2008, a Organização Mundial da Saúde (OMS) redefiniu os critérios para classificação das SMDs, dividindo-as em sete subgrupos. Nessa classificação foram incluídos novos aspectos imunofenotípicos, genéticos, citomorfológicos e moleculares, o que tornou o domínio e o acesso a tecnologias de ponta imprescindíveis para a realização do diagnóstico das SMDs. As síndromes mielodisplásicas (SMD) constituem um grupo de doenças hematológicas caracterizadas por citopenias crônicas, associadas a uma maturação celular anormal. Há quatro estágios: baixo risco, riscos intermediário-1 e 2 e alto risco. O diagnóstico definitivo, em especial nos casos de baixo risco, deve considerar a exclusão de causas não clonais que podem, através de alterações dismielopoéticas reativas, simular a mielodisplasia, tais como infecções virais, principalmente pelo HIV. O transplante de células-tronco hematopoéticas (TCTH) é a única alternativa curativa para Síndrome Mielodisplásica (SMD), porém muitos pacientes não são elegíveis para esta opção, pois existem diversos fatores limitantes, principalmente no caso de pacientes com SMD de baixo risco.¨

 

■ Myelodysplastic syndrome from theoretical review to clinical application view

Mohammad AA.

Oncol Rev. 2018 Dec 7;12(2):397.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291758/

 

■ Myelodysplastic syndromes in Latin America: state of the art

Crisp R, Grille S, Belli C, Diaz L et al

Latin-American Group for Myelodysplastic Syndromes GLAM.

Blood Adv. 2018 Nov 30;2(Suppl 1):60-6

http://www.bloodadvances.org/content/2/Supplement_1/60?sso-checked=true

 

■ Severe eosinophilia in myelodysplastic syndrome with a defined and rare cytogenetic abnormality

Rai S, Espinoza JL, Morita Y, Tanaka H, Matsumura I.

Front Immunol. 2019 Jan 9;9:3031.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334338/

 

■ Complex karyotype in myelodysplastic syndrome: diagnostic procedure and prognostic susceptibility

Shahjahani M, Hadad EH, Azizidoost S, Nezhad KC, Shahrabi S.

Oncol Rev. 2019 Feb 4;13(1):38

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379782/

 

■ Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

Aleshin A, Greenberg PL.

Blood Adv. 2018 Oct 23;2(20):2787-2797

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199665/

 

■ Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification an management

G Montalban, G Garcia-Manero

American Journal of Hematology dec 2017

 

■ Myelodysplastic syndromes over time: a comparison of two patient cohorts

Oster HS, Svorai-Litvak S, Kirgner I, Kolomansky A, Siegel RS, Mittelman M.

Isr Med Assoc J. 2018 Oct;20(10):608-612.

https://www.ima.org.il/FilesUpload/IMAJ/0/310/155136.pdf

 

■ Myelodysplastic syndromes current treatment algorithm 2018

D P Steensma

Blood Cancer Journal 2018, Article number47

https://www.nature.com/articles/s41408-018-0085-4

 

■ Thrombocytopenia in patients with myelodysplastic syndromes: still an unsolved problem

M Basood, H S Osler, M Mittelman

Mediterr J Hematol Infect Dis 2018: vol 10 (1): e2018046

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039085/

 

■ Practical strategies for management of lenalidomide-associated cytopenias in myelodysplastic syndromes with del (5q)

Kurtin SE, Ridgeway JA, Tinsley S.

J Adv Pract Oncol. 2017 Nov-Dec;8(7):721-728

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188096/

 

■ The rising era of immunecheckpoint inhibitors in myelodysplastic syndromes

Chokr N, Patel R, Wattamwar K, Chokr S.

Adv Hematol. 2018 Nov 1;2018:2458679. doi: 10.1155/2018/2458679

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241340/

 

■ Routes of clonal evolution into complex karyotypes in myelodysplastic syndrome patients with 5q deletion

Feurstein S, Thomay K, Hofmann W, Buesche G et al

Int J Mol Sci. 2018 Oct 21;19(10). pii: E3269

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214088/

 

■ Hematological malignancy in adults with a family predisposition

Bochtler T, Haag GM, Schott S, Kloor M, Krämer A, Müller-Tidow C.

Dtsch Arztebl Int. 2018 Dec 14;115(50):848-854

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375069/

 

■ Iron overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment

Lyle L, Hirose A.

J Adv Pract Oncol. 2018 May-Jun;9(4):392-405

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347085/

 

■ Del(5q) myelodysplastic syndrome combined with pure  red cell aplasia

Joowon Park

Blood Res. 2018 Jun; 53(2): 104

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021577/

 

■ Clinical, hematological, and cytogenetic profile of asult myelodysplastic syndrome in a tertiary care center

Santhosh Narayanan

J Blood Med. 2017; 8: 21–27

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328424/

 

■ Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II)

Uwe Wollina, Gesina Hansel, Anja Baunacke, Georgi Tchernev

Clin Cosmet Investig Dermatol. 2017; 10: 195–198

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478159/

 

■ Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes

Duarte, Fernando Barroso et al.

Rev. Assoc. Med. Bras., Oct 2016, vol.62, suppl.1, p.25-2

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302016001200025&lng=en&nrm=iso&tlng=en

 

■ Clinical utility of lenalidomide in the treatment of myelodysplastic syndrome

Abdallah Abou Zahr, Ehab Saad Aldin, Rami S Komrokji, Amer M Zeidan

J Blood Med. 2015; 6: 1–16

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278786/

 

■ Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases: challenges and difficulties in a large and emerging country.

Velloso, E.D.R.P. et al.

Braz. J. Med. Biol. Res., Jan 2013, vol.46, no.1, p.85-90

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000100085&lng=en&nrm=iso

 

■ Síndrome de Sweet e policondrite recidivante reveladores de síndrome mielodisplásica.

Diamantino, Filipa da Encarnação Roque, Raimundo, Pedro Manuel Oliveira da Cunha and Fidalgo, Ana Isabel Pina Clemente

An. Bras. Dermatol., Ago 2011, vol.86, no.4, suppl.1, p.173-177

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962011000700045&lng=en&nrm=iso

 

■ Transplante de célula-tronco hematopoética para síndrome mielodisplásica

Tabak, Daniel G., Pereira, Simone C. M. and Nogueira, Marta C.

Rev. Bras. Hematol. Hemoter., Maio 2010, vol.32, suppl.1, p.66-70

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842010000700012&lng=en&nrm=iso

 

■ Does soy increase blood counts in myelodysplastic syndromes?

Viana, T. A. O. F. et al.

  1. Bras. Patol. Med. Lab., Oct 2010, vol.46, no.5, p.383-390

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442010000500007&lng=en&nrm=iso&tlng=en

 

■ Síndromes mielodisplásicas: aspectos moleculares, laboratoriais e a classificação OMS 2008

Moraes, Ana Carolina R. et al.

Rev. Bras. Hematol. Hemoter., 2009, vol.31, no.6, p.463-470

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000600016&lng=en&nrm=iso

 

■ Síndromes mielodisplásicas e mielodisplásicas/mieloproliferativas

Vassallo, José and Magalhães, Silvia M. M.

Rev. Bras. Hematol. Hemoter., Ago 2009, vol.31, no.4, p.267-272

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000400015&lng=en&nrm=iso

 

■ Aloimunidade contra antígenos HLA de classe I em pacientes com síndromes mielodisplásicas e anemia aplástica

Arruda, Daisy M. M. et al.

Rev. Bras. Hematol. Hemoter., Fev 2008, vol.30, no.1, p.18-23

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000100007&lng=en&nrm=iso

 

■ by Dr Paulo Fernando Leite

Cardiologia – Centro Médico Unimed BH

Rua Gonçalves Dias 202

Belo Horizonte/MG/Brasil

tel 40204020

CRMMG: 7026

Email: pfleite1873@gmail.com